deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03519997

A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

Sponsor: David Hsieh

Conditions Hepatocellular Carcinoma
Interventions Bavituximab Pembrolizumab
Updated 17 times since 2018 Last updated: Jan 29, 2026 Started: Apr 26, 2018 Primary completion: Apr 21, 2023 Completion: Apr 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by David Hsieh and has accumulated 17 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2018 – ~Oct 2019 · 16 months · monthly snapshot~Oct 2019 – ~Jun 2020 · 8 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Jan 2022 · 7 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jun 2023 · 12 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jun 2024 · 8 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2025 · 13 months · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

17 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Oct 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  5. Jun 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

  6. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  8. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  9. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  10. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  11. Oct 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  12. Jun 2018 — Oct 2019 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • David Hsieh
  • Merck Sharp & Dohme LLC
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations